Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E M KELLY

Showing results (81-90 of 108) with videos related to

Pageof 11
Sort By:
Molecular Pharmacology|August 12, 2004
An investigation of the neuroprotective effects of tetracycline derivatives in experimental models of retinal cell deathDarryl C Baptiste, Andrew T E Hartwick, Christine A B Jollimore, et al.
Molecules (Basel, Switzerland)|January 24, 2020
Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and InflammationDinesh Thapa, Elizabeth A Cairns, Anna-Maria Szczesniak, et al.
European Journal of Pharmacology|April 23, 2014
Cannabinoid and lipid-mediated vasorelaxation in retinal microvasculatureJessica MacIntyre, Alex Dong, Alex Straiker, et al.
Investigative Ophthalmology & Visual Science|July 31, 2002
Comparison of the neuroprotective effects of adrenoceptor drugs in retinal cell culture and intact retinaDarryl C Baptiste, Andrew T E Hartwick, Christine A B Jollimore, et al.
Prostaglandins & Other Lipid Mediators|September 21, 2018
Inflammation and CB<sub>2</sub> signaling drive novel changes in the ocular lipidome and regulate immune cell activity in the eyeJ T Toguri, E Leishman, A M Szczesniak, et al.
Neuropharmacology|August 30, 2016
Cannabinoid 2 receptor is a novel anti-inflammatory target in experimental proliferative vitreoretinopathyAnna-Maria Szczesniak, Richard F Porter, James T Toguri, et al.
Frontiers in Molecular Neuroscience|November 5, 2019
Indomethacin Enhances Type 1 Cannabinoid Receptor SignalingRobert B Laprairie, Kawthar A Mohamed, Ayat Zagzoog, et al.
Clinical & Experimental Ophthalmology|November 29, 2018
Effects of intravitreal bevacizumab in Gram-positive and Gram-negative models of ocular inflammationJ Daniel Lafreniere, James T Toguri, Rishi R Gupta, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|July 19, 2017
The In Vivo Effects of the CB<sub>1</sub>-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive MiceElizabeth A Cairns, Anna-Maria Szczesniak, Alex J Straiker, et al.
Clinical and Translational Medicine|November 6, 2022
Comprehensive profiling of the human viral exposome in households containing an at-risk child with mitochondrial disease during the 2020-2021 COVID-19 pandemicEliza M Gordon-Lipkin, Christopher S Marcum, Shannon Kruk, et al.
Pageof 11

Showing results (81-90 of 108) with videos related to

Sort By:
Pageof 11
Molecular Pharmacology|August 12, 2004
An investigation of the neuroprotective effects of tetracycline derivatives in experimental models of retinal cell deathDarryl C Baptiste, Andrew T E Hartwick, Christine A B Jollimore, et al.
Molecules (Basel, Switzerland)|January 24, 2020
Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and InflammationDinesh Thapa, Elizabeth A Cairns, Anna-Maria Szczesniak, et al.
European Journal of Pharmacology|April 23, 2014
Cannabinoid and lipid-mediated vasorelaxation in retinal microvasculatureJessica MacIntyre, Alex Dong, Alex Straiker, et al.
Investigative Ophthalmology & Visual Science|July 31, 2002
Comparison of the neuroprotective effects of adrenoceptor drugs in retinal cell culture and intact retinaDarryl C Baptiste, Andrew T E Hartwick, Christine A B Jollimore, et al.
Prostaglandins & Other Lipid Mediators|September 21, 2018
Inflammation and CB<sub>2</sub> signaling drive novel changes in the ocular lipidome and regulate immune cell activity in the eyeJ T Toguri, E Leishman, A M Szczesniak, et al.
Neuropharmacology|August 30, 2016
Cannabinoid 2 receptor is a novel anti-inflammatory target in experimental proliferative vitreoretinopathyAnna-Maria Szczesniak, Richard F Porter, James T Toguri, et al.
Frontiers in Molecular Neuroscience|November 5, 2019
Indomethacin Enhances Type 1 Cannabinoid Receptor SignalingRobert B Laprairie, Kawthar A Mohamed, Ayat Zagzoog, et al.
Clinical & Experimental Ophthalmology|November 29, 2018
Effects of intravitreal bevacizumab in Gram-positive and Gram-negative models of ocular inflammationJ Daniel Lafreniere, James T Toguri, Rishi R Gupta, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|July 19, 2017
The In Vivo Effects of the CB<sub>1</sub>-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive MiceElizabeth A Cairns, Anna-Maria Szczesniak, Alex J Straiker, et al.
Clinical and Translational Medicine|November 6, 2022
Comprehensive profiling of the human viral exposome in households containing an at-risk child with mitochondrial disease during the 2020-2021 COVID-19 pandemicEliza M Gordon-Lipkin, Christopher S Marcum, Shannon Kruk, et al.
Pageof 11